TIRZEPATIDE.CFD is an independent information website. We do not sell, supply or prescribe any substance.
TIRZEPATIDE
.CFD
Languages
For education only. Tirzepatide is a prescription medicine in many countries; research-grade material is not a licensed product. Nothing here is medical advice.
The Evidence

Tirzepatide Clinical Trial Results

Reading the numbers: These are average results from controlled trials in selected participants under medical care. Individual responses vary widely, and the figures are not a guide to self-treatment.

Few metabolic drugs have been tested as thoroughly as tirzepatide. The trials below are the main peer-reviewed publications, grouped by topic. Results are rounded and dose groups simplified; the original papers are listed at the end.

Early Trials

In the 2018 Phase 2 trial in type 2 diabetes (The Lancet), the effect on HbA1c rose with the dose and did not level off. After 26 weeks, HbA1c fell by between 1.06 and 1.94 percentage points on tirzepatide, compared with 0.06 on placebo and 1.21 on dulaglutide. Gastrointestinal effects were the most common side effects and were more frequent at higher doses.

SURPASS: Type 2 Diabetes

  • SURPASS-1 (The Lancet, 2021): as the only treatment in 478 adults, tirzepatide lowered HbA1c by 1.87 to 2.07 points after 40 weeks, against a small rise on placebo. Weight fell by 7.0 to 9.5 kg.
  • SURPASS-2 (NEJM, 2021): in 1,879 adults already taking metformin, HbA1c fell by 2.01 to 2.30 points, against 1.86 with semaglutide 1 mg. Weight loss was 1.9 to 5.5 kg greater than with semaglutide.
  • SURPASS-3 (The Lancet, 2021): tirzepatide lowered HbA1c and weight more than the long-acting insulin degludec.
  • SURPASS-4 (The Lancet, 2021): in people with raised cardiovascular risk, tirzepatide outperformed insulin glargine on HbA1c, and the trial found no increase in major cardiovascular events.

SURMOUNT-1: Obesity

This 72-week trial (NEJM, 2022) enrolled 2,539 adults with obesity, or with overweight and a related condition, who did not have diabetes. Average starting weight was 104.8 kg.

  • Average weight change was −15.0% with 5 mg, −19.5% with 10 mg and −20.9% with 15 mg, against −3.1% with placebo.
  • In the 15 mg group, 57% of participants lost at least 20% of their body weight.
  • Side effects that led people to stop treatment affected 4 to 7% of participants on tirzepatide and 2.6% on placebo.
  • A three-year extension in people with prediabetes (NEJM, 2025) found that 1.3% of those on tirzepatide developed type 2 diabetes, against 13.3% on placebo.

Stopping Treatment: SURMOUNT-4

After 36 weeks of treatment, participants in SURMOUNT-4 (JAMA, 2024) were either kept on tirzepatide or switched to placebo. Over the next year, those who continued lost a further 5.5% of their weight, while those switched to placebo regained 14.0%. The trial showed that the weight effect depends on continued treatment.

Head to Head with Semaglutide: SURMOUNT-5

In 751 adults with obesity but no diabetes (NEJM, 2025), average weight change after 72 weeks was −20.2% with tirzepatide and −13.7% with semaglutide. Waist size fell by 18.4 cm and 13.0 cm respectively. Both drugs mainly caused gastrointestinal side effects, most often during dose increases.

Other Conditions

  • Sleep apnoea (SURMOUNT-OSA, NEJM, 2024): after 52 weeks, breathing interruptions during sleep fell by 25 to 29 events per hour, against about 5 with placebo.
  • Heart failure (SUMMIT, NEJM, 2025): in 731 people with obesity and heart failure with preserved ejection fraction, cardiovascular death or worsening heart failure occurred in 9.9% on tirzepatide and 15.3% on placebo.
  • Liver disease (SYNERGY-NASH, NEJM, 2024): in this Phase 2 trial, MASH resolved without worsening of fibrosis in 44 to 62% of participants on tirzepatide, against 10% on placebo.
  • Cardiovascular outcomes (SURPASS-CVOT, NEJM, 2025): in 13,165 analysed patients with type 2 diabetes and heart disease, heart attack, stroke or cardiovascular death occurred in 12.2% on tirzepatide and 13.1% on dulaglutide. Tirzepatide met the goal of being no worse than dulaglutide, but the difference was not large enough to show it was better.

Open Questions

  • How safe and effective treatment is over many years, beyond the three-year data now available.
  • How best to maintain results after stopping, since weight tends to return.
  • How much of the weight lost is lean tissue, and what that means for older people.
  • Whether the benefits seen in specific trials apply to wider and more diverse populations.

Main Sources

  1. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID 30473097
  2. Frias JP, et al. Efficacy and safety of LY3298176 in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392:2180-2193. PMID 30293770
  3. Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PMID 32730231
  4. Rosenstock J, et al. Tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398:143-155. PMID 34186022
  5. Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503-515. PMID 34170647
  6. Ludvik B, et al. Once-weekly tirzepatide versus once-daily insulin degludec (SURPASS-3). Lancet. 2021;398:583-598. PMID 34370970
  7. Del Prato S, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021;398:1811-1824. PMID 34672967
  8. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216. PMID 35658024
  9. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331:38-48. PMID 38078870
  10. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391:1193-1205. PMID 38912654
  11. Loomba R, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299-310. PMID 38856224
  12. Packer M, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392:427-437. PMID 39555826
  13. Jastreboff AM, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392:958-971. PMID 39536238
  14. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26-36. PMID 40353578
  15. Nicholls SJ, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393:2409-2420. PMID 41406444